Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Allan K. Uldam is active.

Publication


Featured researches published by Allan K. Uldam.


Journal of Pharmacology and Experimental Therapeutics | 2006

Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2R,3R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist

Kimberly E. Vanover; David M. Weiner; Malath Makhay; Isaac Veinbergs; Luis R. Gardell; Jelveh Lameh; Andria L. Del Tredici; Fabrice Piu; Hans H. Schiffer; Thomas R. Ott; Ethan S. Burstein; Allan K. Uldam; Mikkel Boas Thygesen; Nathalie Schlienger; Carl Magnus Andersson; Thomas Son; Scott C. Harvey; Susan B. Powell; Mark A. Geyer; Bo-Ragner Tolf; Mark R. Brann; Robert E. Davis

The in vitro and in vivo pharmacological properties of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103) are presented. A potent 5-hydroxytryptamine (5-HT)2A receptor inverse agonist ACP-103 competitively antagonized the binding of [3H]ketanserin to heterologously expressed human 5-HT2A receptors with a mean pKi of 9.3 in membranes and 9.70 in whole cells. ACP-103 displayed potent inverse agonist activity in the cell-based functional assay receptor selection and amplification technology (R-SAT), with a mean pIC50 of 8.7. ACP-103 demonstrated lesser affinity (mean pKi of 8.80 in membranes and 8.00 in whole cells, as determined by radioligand binding) and potency as an inverse agonist (mean pIC50 7.1 in R-SAT) at human 5-HT2C receptors, and lacked affinity and functional activity at 5-HT2B receptors, dopamine D2 receptors, and other human monoaminergic receptors. Behaviorally, ACP-103 attenuated head-twitch behavior (3 mg/kg p.o.), and prepulse inhibition deficits (1-10 mg/kg s.c.) induced by the 5-HT2A receptor agonist (±)-2,5-dimethoxy-4-iodoamphetamine hydrochloride in rats and reduced the hyperactivity induced in mice by the N-methyl-d-aspartate receptor noncompetitive antagonist 5H-dibenzo[a,d]cyclohepten-5,10-imine (dizocilpine maleate; MK-801) (0.1 and 0.3 mg/kg s.c.; 3 mg/kg p.o.), consistent with a 5-HT2A receptor mechanism of action in vivo and antipsychotic-like efficacy. ACP-103 demonstrated >42.6% oral bioavailability in rats. Thus, ACP-103 is a potent, efficacious, orally active 5-HT2A receptor inverse agonist with a behavioral pharmacological profile consistent with utility as an antipsychotic agent.


Life Sciences | 2001

Exploring the potential for subtype-selective muscarinic agonists in glaucoma

Daniel W. Gil; Tracy A. Spalding; Alex Kharlamb; Niels Skjaerbaek; Allan K. Uldam; Carol Trotter; Donghui Li; Elizabeth Woldemussie; Larry A. Wheeler; Mark R. Brann

Pilocarpine has been used to lower intraocular pressure (IOP) in glaucoma patients for more than 100 years. Since the identification of five muscarinic receptor subtypes, there has been an interest in separating the IOP-lowering effects from the ocular side effects of pupil constriction and lens accommodation. However, all these actions seem to be mediated by the M3 receptor. A novel muscarinic receptor agonist, AGN 199170, that has no activity on the M3 subtype was compared to pilocarpine in a monkey glaucoma model. This compound lowered IOP suggesting that muscarinic agonists targeted at muscarinic receptors other than the M3 subtype may be able to selectively lower IOP.


Archive | 2004

Selective serotonin 2A/2C receptor inverse agonists as therapeutics for neurodegenerative diseases

David M. Weiner; Robert E. Davis; Mark R. Brann; Carl-Magnus A. Andersson; Allan K. Uldam


Archive | 2001

Azacyclic compounds for use in the treatment of serotonin related diseases

Carl-Magnus A. Andersson; Glenn Croston; Eva-Louise Hansen; Allan K. Uldam


Archive | 2011

Methods of treatment using selective 5-ht2a inverse agonists

Carl-Magnus A. Andersson; Glenn Croston; Eva Louise Hansen; Allan K. Uldam


Archive | 2004

Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen Selective serotonin 2a / 2c receptor inverse agonists as therapeutics for neurodegenerative diseases

David M. Weiner; Robert E. Davis; Mark R. Brann; Norman Nash; Carl-Magnus A. Andersson; Allan K. Uldam


Archive | 2004

Selektive serotonin 2a/2c inverse rezeptoragonisten als therapeutika für neurodegenerative erkrankungen

David M. Weiner; Robert E. Davis; Mark R. Brann; Norman Nash; Carl Magnus Andersson; Allan K. Uldam


Archive | 2004

Agonistas inversos selectivos de los receptores 2a o 2c de serotonina utilzados como agentes terapéuticos para enfermedades neurodegenerativas.

Carl-Magnus A. Andersson; Mark R. Brann; Robert E. Davis; Norman Nash; Allan K. Uldam; M.David Weiner


Archive | 2004

Selektive Serotonin-2A/2C-Rezeptor-Inversagonisten als Therapeutika für neurogenerative Erkrankungen

M.David Weiner; Robert E. Davis; Mark R. Brann; Norman Nash; Carl-Magnus A. Andersson; Allan K. Uldam


Archive | 2004

Selective serotomin - 2A / 2C - receptor - inverse - agonists as therapeutic agents for neurodegenerative diseases

Robert E. Davis; David M. Weiner; Mark R. Brann; Norman Nash; Carl-Magnus A. Andersson; Allan K. Uldam

Collaboration


Dive into the Allan K. Uldam's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Norman Nash

ACADIA Pharmaceuticals Inc.

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Eva Louise Hansen

ACADIA Pharmaceuticals Inc.

View shared research outputs
Top Co-Authors

Avatar

Glenn Croston

ACADIA Pharmaceuticals Inc.

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Carol Trotter

ACADIA Pharmaceuticals Inc.

View shared research outputs
Researchain Logo
Decentralizing Knowledge